Explore seven healthcare stocks that are under US$50

Highlights

• Halozyme Therapeutics’ (NASDAQ:HALO) GAAP net income was US$91.5 million in Q2, 2021, compared to US$25.8 million in Q2, 2020.
• Adaptive Biotechnologies Corporation’s (Nasdaq:ADPT) revenue for Q2, 2021, was US$38.5 million, up 83% YoY.
• Premier, Inc’s (NASDAQ:PINC) GAAP net revenue for Q4, 2021, was US$481.5 million, up 40% YoY.

The healthcare sector covers pharmaceuticals, medical devices, drugs, vaccines, hospitals, health insurance, etc. These companies are always in demand due to the everyday need for drugs and other healthcare products. In addition, the sector saw robust growth during the pandemic.

Here we explore seven healthcare stocks that are under US$50.

Halozyme Therapeutics, Inc. (NASDAQ:HALO)

HALO is a California-based biotechnology company and cancer drugs.

The stocks traded at US$39.60 at 9.37 am ET on Sep 28, down 1.44 percent over the closing price of Sep 27.

The revenue for Q2, 2021 was US$136.5 million compared to US$55.2 million in Q2, 2020. The GAAP net income was US$91.5 million in Q2, 2021, compared to US$25.8 million in Q2, 2020. The GAAP earnings per share were US$0.62 in Q2, 2021, compared to US$0.19 in Q2, 2020.

The market cap is US$5 billion, while the P/E and the forward P/E one-year ratios are 25.74 and 22.06, respectively. The EPS is US$1.56. The stock’s 52-week highest and lowest prices were US$56.40 and US$25.69, respectively.

Adaptive Biotechnologies Corporation (Nasdaq:ADPT)

ADPT is a Washington-based biotechnology company and develops immune system-based medicines. The stock traded at US$34.46 at 9.49 am ET on Sep 28, down 3.82% from its previous close.

The revenue for Q2, 2021, was US$38.5 million, up 83% YoY. The net loss was US$49.3 million in Q2, 2021, compared to US$33.5 million in Q2, 2020.

Adjusted EBITDA (non-GAAP) was a loss of US$35.6 million in the period against a loss of US$28.5 million in Q2 of the prior year.

The market cap is US$4.8 billion. The EPS is US$-1.24. The 52-week highest and lowest stock prices were US$71.25 and US$9.73, respectively.

TG Therapeutics, Inc. (NASDAQ:TGTX)

TGTX is a US-based biopharma company and develops novel treatments for B-cell malignancies and autoimmune diseases. The stock traded at US$34.04 at 9.59 am ET on Sep 28, down 1.62% over Sep 27 closing price.

Product revenue in Q2, 2021, was US$1.5 million compared to zero in Q2, 2020. Net loss was US$78.5 million compared to US$52.9 million in Q2, 2020.

The market cap is US$4.8 billion. The EPS is US$-2.72. The highest and lowest stock prices in the last 52 weeks were US$56.74 and US$21.06, respectively.

Source: Pixabay.

Premier, Inc. (NASDAQ:PINC)

PINC is a healthcare company and has an alliance with over 4,400 US hospitals.

The stock traded at US$38.70 at 10.07 am ET on Sep 28, down 0.31%, over yesterday’s closing price. The GAAP net revenue for Q4, 2021, was US$481.5 million, 40 percent up YoY. The GAAP net income for the period was US$50.7 million, down from US$55.4 million in Q4, 2020. GAAP EPS was US$0.41 in Q4, 2021, compared to a net loss of US$0.31 per share in Q4, 2020.

The market cap is US$4.7 billion. The P/E and the forward P/E one-year ratios are 15.1 and 16.59, respectively. The EPS is US$2.57, and the annual dividend is US$0.80.

Also read: Top five biotechnology stocks to explore that are under US$100

Boston Scientific Corporation (NYSE:BSX)

BSX is a Massachusetts-based company and manufactures medical devices.

The stock traded at US$43.709 at 11.16 am ET on Sep 28, down 1.69% over yesterday’s closing price. It reported net sales of US$3.077 billion in Q2, 2021. The GAAP net income was US$0.12 per share in the quarter.

The market cap is US$62.2 billion. The P/E and the forward P/E one-year ratios are 132.58 and 27.61, respectively. The EPS is US$0.33. The 52-week highest and lowest stock prices were US$46.28 and US$32.99, respectively.

Source: Pixabay.

Pfizer Inc. (NYSE:PFE)

PFE is a New York-based pharmaceutical company and manufactures medicines and other healthcare products. Its stock traded at US$42.87 at 11.22 am ET on Sep 28, down 1.69% over yesterday’s closing price.

The company reported revenue of US$18.9 billion in Q2, 2021, up 92% YoY. The reported net income in Q2, 2021, was US$5.5 billion, up 59% YoY. The reported diluted earnings per share were US$0.98, up 58% YoY.

The market cap is US$239 billion. The P/E and the forward P/E one-year rations are 18.37 and 10.50, respectively. The EPS is US$2.33, and the annual dividend is US$1.56. The 52-week highest and lowest stock prices were US$51.86 and US$33.36, respectively.

Also read: Top six pharmaceutical stocks to watch in September

Envista Holdings (NYSE:NVST)

NVST, a California-based company, manufactures dental consumables, solutions, technology, and services. The stock traded at US$42.14 at 11.31 am ET on Sep 28, down 0.52% over yesterday’s closing price.

The company reported sales of US$740.1 million in Q2, 2021, an increase of 104.4% YoY. Net income was US$90.1 million, or $0.51 per diluted share, in the period. And adjusted net income was US$94.2 million, or US$0.53 per diluted share, in Q2, 2021. Adjusted EBITDA was US$140.4 million in the quarter as compared to US$1.0 million in Q2, 2020.

The market cap is US$6.8 billion. The P/E and the forward P/E one-year ratios are 23.78 and 21.68, respectively. The EPS is US$1.78. The 52-week highest and lowest stock prices were US$46.52 and US$23.59, respectively.

Bottomline

The healthcare sector received a major boost after governments awarded new contracts to companies to develop drugs against Covid-19. The sector saw massive government and private investments during the pandemic. It is expected to grow further as more government financial support is in the pipeline. However, investors should carefully evaluate the companies before investing.